# The In Vivo Evaluation on Total Components from Extract ofAconitum Based on a New Analytic Method of Area under Absorbance-Wavelength Curve

Authors: Miaomiao Yang; Huasong Wu; Xiaodong Li
Journal: Journal of Spectroscopy
 (2019)

---

## Abstract

Objective. To study oral pharmacokinetics of Aconitum extract in randomized Sprague-Dawley (SD) rats and observe the profile change in vivo between plasma concentration and time with an aim to disclose relevant delivery rule for total components from Aconitum extract and finally to evaluate the research of Aconitum sustained-release preparation. Methods. Randomized rats were administered orally with the single and multiple dose of Aconitum extract based on the clinical use of Aconitum injection. Blood samples were collected at predetermined interval time from an eye of rats. The concentration of total components in those samples was determined by a new analytic method of area under absorbance-wavelength curve, the data were analyzed by Drug and Statistics software, and then the pharmacokinetic parameters and compartment model were acquired and compared, respectively. Results. The pharmacokinetic parameters of single and multiple doses were similar, and both of them showed characteristics of the one-compartment model. Cav, DF, and AUCss were (2.075 ± 0.282) µg/ml, (2.405 ± 0.175), and (24.901 ± 0.422) µg/ml/h, respectively. However, the concentrations of total components in the fifth and sixth day were 0.32 and 0.44 µg/ml, which were lower than the value of Cav. Conclusion. The method of AUAWC is feasible for the pharmacokinetics study in vivo analysis on total components of Aconitum with good sensitivity, specificity, and repeatability. The results demonstrated that both absorption and elimination of total components from Aconitum extract in rats were rapid and pharmacokinetic behavior was consistent at the level of single and multiple doses, which confirms that Aconitum injection is available to transform the oral sustained-release preparation. This will bring a good instruction to the research of sustained-release preparation of traditional Chinese medicine (TCM), which still lacks of an evaluation method available for total components in vivo analysis.


---

## Body

## 1. Introduction

Aconitum is a famous traditional Chinese medicine that had been used extensively for centuries to treat pain resulted from arthritis and cancer and to strengthen the function of the heart [1–4]. The main bioactive components of Aconitum are Aconitum alkaloids with a narrow therapeutic index, and the activity is closely related to the structure which differs from the number, type, and position of the substituents [5]. Aconitum injection composed of raw Chuanwu and Caowu, a kind of traditional Chinese medicine injection, is used for treatment of serious pain in the terminal gastric and liver cancer and has significant analgesic effect without addiction [6–9]. Although it has such promising therapeutic effects, its potential neurotoxicity and cardiotoxicity are frequently observed in clinics [10–13]. Aconitum injection is intramuscular in clinic with once or twice a day at 1∼2 ml every time according to the standard of the ministry of traditional Chinese medicines [14]. But, it has no good compliance for the patient and is only injected through the doctors in hospital. Therefore, it is reasonable for us to study oral Aconitum sustained-release preparation transformed from Aconitum injection due to its digestive tract treatment for serious pain from terminal gastric and liver cancer.Pharmacokinetic study is very important for the development of sustained-release preparation. However, there is no good effectively analytic evaluation method to be used for the pharmacokinetics of total components of TCM. This is the major reason why the sustained-release preparations of TCM were variously reported in references but little marketed in clinic. Up to now, despite many related theories and hypotheses about pharmacokinetics of TCM have been reported to explain its pharmacokinetic behavior, the substantial progresses for total components have not been broken through in nature [15–20]. There were many pharmacokinetic studies on Aconitum from references [21–24] but still lacking of related information for total components of Aconitum. It was reported that Aconitum alkaloids were absorbed and metabolized in vivo rapidly, which were all based on some certain individual alkaloids with clear chemical structure such as aconitine, meaconitine, and hyaconitine by high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (HPLC-MS) [25–27]. Nevertheless, the pharmacokinetic results of various individual components are difficult to reasonably clarify the total pharmacokinetic characteristics of TCM with complicated components. Hence, it is very necessary and urgent to establish an analytical method for pharmacokinetic study on total components of Aconitum.Area under absorbance-wavelength curve (AUAWC) is an analytical method based on UV-visible (UV-Vis) spectrophotometry, which can be used for simultaneous determination of total components of TCM with a combination of mathematics and computer technology, and has being used successfully in our group. At present, despite the methods of HPLC and HPLC-MS are being used in more and more analytical fields, UV-Vis spectrophotometry is also applied for its special merits, especially analysis such as total flavonoids, total alkaloids, and total saponins dealing with total components. In vivo, though part of total components may possibly be metabolized as metabolites, the mother nuclear structure of metabolite does not always change and the absorption behavior in UV-Vis spectrophotometry is generally the same. Therefore, AUAWC can accurately illustrate the delivery tendency of total components concentration including metabolites in plasma with time change. It is proportional to the concentration of total components, which was proposed in 2012 and confirmed from the theory based on Lambert–Beer’s equation with EL constant [28, 29], as follows:(1)AUAWC=EL⋅Ctotal.And, a series of trials related to AUAWC or its combination with HPLC were well performed and reported in the Journal of Spectroscopy in 2013 [30] and some good Chinese core journals, such as the content determination of total components in TCMs [31–33] and the studies on in vitro release tests [34–36] and in vivo pharmacokinetics [37–39] of total components in compounds preparations of TCMs. As for the operation procedure, firstly, AUAWC can be calculated through Origin software. Then, the AUAWC of total components can be obtained after a subtraction of the AUAWC of the drug’s plasma sample to the AUAWC of the blank plasma sample, as shown in Figure 1. Thirdly, the concentration of total components is calculated through a linear equation in which the concentration of total components is the AUAWC at certain time. Subsequently, the profile between concentration and time can be drawn, and the pharmacokinetic parameters be obtained through DAS software, illustrating absorption, distribution, metabolism, and excretion for total components from TCM and their final delivery rule in vivo.Figure 1
AUAWC of blank plasma and drug plasma sample. (1) AUAWC of drug plasma: a full spectrum scanning for the plasma sample from the rat with the administered drug. (2) AUAWC of blank plasma: a full spectrum scanning for the plasma sample from the rat without drug.Nowadays, cancer increasingly affects people’s health and even becomes the leading cause of death with no presently good treatment criteria. Thus, in this study, the total components in rats fromAconitum extract, which was prepared according to the technique of Aconitum injection in the standard of the ministry of traditional Chinese medicines, were determined by the method of AUAWC. After an oral administration with the single and multiple doses of Aconitum extract, the pharmacokinetic parameters of total components will be analyzed to search for Aconitum's delivery rule in vivo, which will be helpful to bring a good research base for the Aconitum sustained-release preparation and a convenient oral administration for the cancer patients.


## 2. Materials and Methods

### 2.1. Apparatus

UV-Vis spectrum scan was measured on a TU-1901 spectrophotometer (Beijing Purkinje General Instrument Co., Ltd.) with the use of a 1.0 cm quartz cell, AR-2140 one millionth of electronic scale (Mettler-Tolido Instruments (Shanghai) Co., Ltd.); VXH-3 micro-vortex mixer (Shanghai Yuejin Medical Device Factory); and TDL-4 low-speed centrifuge (Shanghai Anting Science Instrument Factory).


### 2.2. Reagents

Aconitine was purchased from the National Institute for Control of Pharmaceutical and Biological Products (Beijing, China). The raw material of Chuanwu and Caowu was purchased from medicine market (Bozhou) and were authenticated by Professor Zehao Huang from Fujian University of Traditional Chinese Medicine. Extract ofAconitum was obtained from the Department of Pharmaceutics of Fujian University of Traditional Chinese Medicine. All other reagents were of analytical grade, and the water used in the experiment was double distilled.


### 2.3. Animals

Healthy Sprague-Dawley rats, weighing 0.20–0.22 kg, were purchased from SLAC Laboratory Animal Company (Shanghai, China, SCXK (HU) 2018-0005). All the rats were allowed to acclimate one week before experiment. All studies were in compliance with the Guidelines for the Care and Use of Laboratory Animals and approved by Institutional Animal Care and Use Committee in XBL-China.


### 2.4. Animal Administration and Sampling

SD rats were randomly divided into nine groups (eight rats each group) based on different interval times, one group of which was regarded as the blank group and the others were administered orally the extract ofAconitum. The rats were fasted overnight and administered Aconitum extract at a single dose of 0.6 mg/kg in the morning, which is equivalent to the one-time dose of Aconitum injection. Blood samples (about 2.5 ml) were collected from intraocular angular veins of each rat and placed into tubes with heparin sodium anticoagulant at predetermined interval times (0, 0.25, 0.5, 1, 2, 4, 6, 8, and 12 h). Then, blood samples were centrifuged immediately at 3800 r/min for 10 min, and the separated plasma samples were stored at −20°C until analysis. The rats were fed to acclimate for one week after taking blood and then administered the Aconitum extract again at a dose of 0.6 mg/kg for 7 d continuously. The blood samples were collected and processed as the same as single dose except the blood samples for stable drug concentration determination, which were taken in the morning of the fifth and sixth day before the rats were administered.


### 2.5. Method Validation

#### 2.5.1. Preparation of Calibration Standards

The reference substance of aconitine was prepared in methanol before use with a total concentration of 213μg/ml. Working solutions were prepared by diluting stock solution with methanol for further concentration series of 42.6, 17.04, 8.52, 4.26, 1.06, and 0.53 μg/ml.


#### 2.5.2. Specificity

Specificity of the method was investigated by comparing chromatograms of processed blank plasma samples, the standard of aconitine, the blank plasma spiked with the aconitine, and plasma after oral administration ofAconitum extract. The AUAWC of plasma samples should be larger than that of blank plasma samples, so the interference of blank plasma can be eliminated by the difference value.


#### 2.5.3. Linearity

In accordance with the UV-Vis spectrophotometry, methanol was used as the blank control. Each 0.2 ml blank plasma was precisely added above series of standard solutions to 4 ml, respectively, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength. An eight-point calibration curve was constructed by plotting the AUAWC against the concentration. The linearity of the calibration curve was evaluated by linear regression analysis.


#### 2.5.4. Recovery

The extraction recovery and relative recovery of aconitine were determined by analyzing six replicates of QC samples at three concentration levels. The extraction recovery was calculated by comparing the AUAWC values (a) of extracted QC samples with those (a) in which the compounds were spiked directly to methanol. The relative recovery was evaluated by comparing the concentration calculated by substituting the AUAWC values (a) into the regression equation with the actual concentration.


#### 2.5.5. Precision

The precision of the method was determined by analyzing QC samples at three concentration levels in six replicates. Intraday precision was assessed from replicate analyses (n=6) of QC samples at each concentration level on the same day. The precision was expressed as relative standard deviation (RSD) for each QC concentration. The precisions were required to be within ±15% RSD.


#### 2.5.6. Difference

The difference of the blank plasma samples from randomized SD rats in a group was determined. The difference could be ignored if the RSD < ±15%.


#### 2.5.7. Stability

The stability of drug plasma samples from rats was determined at different time periods, including their stability after three freeze-thaw cycles with a frozen temperature of −20°C and the stability of processed samples kept at room temperature for 8 h. Samples were considered to be stable if the values were within requirement of precision (<±15% RSD).


#### 2.5.8. Sample Preparation and Test

A plasma sample of 0.2 ml was precisely diluted with methanol to 4 ml, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then, supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength with methanol as a blank control.


#### 2.5.9. Pharmacokinetics Study

The values of AUAWC from the blank plasma group and drug groups at different interval time periods were calculated using Origin software. When the mean AUAWC values of drug group were subtracted from that of the blank group, respectively, the increased AUAWC caused by total components was obtained correspondingly and then substituted into the linear equation to get the total components concentration in vivo. The pharmacokinetic models (one- versus two-compartment) were compared according to the AIC rule, with minimum AIC values being regarded as the best representation of the blood concentration-time dynamic data. A compartmental model of total components in rats was proposed by the DAS software. The pharmacokinetic parameters of total components in rats were expressed as mean ± RSD and were compared by the unpaired Student’st-test using the Statistical Package for the Social Science (SPSS, version 18.0). The result was obtained according to the process as showed in Figure 2.Figure 2
The in vivo analysis process of total components by the new method of AUAWC. (1) UV-Vis spectrophotometer for a full spectrum scanning; (2) exported .xl data files and preprocessed; (3) the data preprocessed are then exported into Origin software; (4) the value of AUAWC then were calculated; (5) the concentration acquired by the regression equation and kinetic time were analyzed by DAS 2.0 software; (6) the pharmacokinetic parameters and the concentration-time curves were known.


## 2.1. Apparatus

UV-Vis spectrum scan was measured on a TU-1901 spectrophotometer (Beijing Purkinje General Instrument Co., Ltd.) with the use of a 1.0 cm quartz cell, AR-2140 one millionth of electronic scale (Mettler-Tolido Instruments (Shanghai) Co., Ltd.); VXH-3 micro-vortex mixer (Shanghai Yuejin Medical Device Factory); and TDL-4 low-speed centrifuge (Shanghai Anting Science Instrument Factory).


## 2.2. Reagents

Aconitine was purchased from the National Institute for Control of Pharmaceutical and Biological Products (Beijing, China). The raw material of Chuanwu and Caowu was purchased from medicine market (Bozhou) and were authenticated by Professor Zehao Huang from Fujian University of Traditional Chinese Medicine. Extract ofAconitum was obtained from the Department of Pharmaceutics of Fujian University of Traditional Chinese Medicine. All other reagents were of analytical grade, and the water used in the experiment was double distilled.


## 2.3. Animals

Healthy Sprague-Dawley rats, weighing 0.20–0.22 kg, were purchased from SLAC Laboratory Animal Company (Shanghai, China, SCXK (HU) 2018-0005). All the rats were allowed to acclimate one week before experiment. All studies were in compliance with the Guidelines for the Care and Use of Laboratory Animals and approved by Institutional Animal Care and Use Committee in XBL-China.


## 2.4. Animal Administration and Sampling

SD rats were randomly divided into nine groups (eight rats each group) based on different interval times, one group of which was regarded as the blank group and the others were administered orally the extract ofAconitum. The rats were fasted overnight and administered Aconitum extract at a single dose of 0.6 mg/kg in the morning, which is equivalent to the one-time dose of Aconitum injection. Blood samples (about 2.5 ml) were collected from intraocular angular veins of each rat and placed into tubes with heparin sodium anticoagulant at predetermined interval times (0, 0.25, 0.5, 1, 2, 4, 6, 8, and 12 h). Then, blood samples were centrifuged immediately at 3800 r/min for 10 min, and the separated plasma samples were stored at −20°C until analysis. The rats were fed to acclimate for one week after taking blood and then administered the Aconitum extract again at a dose of 0.6 mg/kg for 7 d continuously. The blood samples were collected and processed as the same as single dose except the blood samples for stable drug concentration determination, which were taken in the morning of the fifth and sixth day before the rats were administered.


## 2.5. Method Validation

### 2.5.1. Preparation of Calibration Standards

The reference substance of aconitine was prepared in methanol before use with a total concentration of 213μg/ml. Working solutions were prepared by diluting stock solution with methanol for further concentration series of 42.6, 17.04, 8.52, 4.26, 1.06, and 0.53 μg/ml.


### 2.5.2. Specificity

Specificity of the method was investigated by comparing chromatograms of processed blank plasma samples, the standard of aconitine, the blank plasma spiked with the aconitine, and plasma after oral administration ofAconitum extract. The AUAWC of plasma samples should be larger than that of blank plasma samples, so the interference of blank plasma can be eliminated by the difference value.


### 2.5.3. Linearity

In accordance with the UV-Vis spectrophotometry, methanol was used as the blank control. Each 0.2 ml blank plasma was precisely added above series of standard solutions to 4 ml, respectively, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength. An eight-point calibration curve was constructed by plotting the AUAWC against the concentration. The linearity of the calibration curve was evaluated by linear regression analysis.


### 2.5.4. Recovery

The extraction recovery and relative recovery of aconitine were determined by analyzing six replicates of QC samples at three concentration levels. The extraction recovery was calculated by comparing the AUAWC values (a) of extracted QC samples with those (a) in which the compounds were spiked directly to methanol. The relative recovery was evaluated by comparing the concentration calculated by substituting the AUAWC values (a) into the regression equation with the actual concentration.


### 2.5.5. Precision

The precision of the method was determined by analyzing QC samples at three concentration levels in six replicates. Intraday precision was assessed from replicate analyses (n=6) of QC samples at each concentration level on the same day. The precision was expressed as relative standard deviation (RSD) for each QC concentration. The precisions were required to be within ±15% RSD.


### 2.5.6. Difference

The difference of the blank plasma samples from randomized SD rats in a group was determined. The difference could be ignored if the RSD < ±15%.


### 2.5.7. Stability

The stability of drug plasma samples from rats was determined at different time periods, including their stability after three freeze-thaw cycles with a frozen temperature of −20°C and the stability of processed samples kept at room temperature for 8 h. Samples were considered to be stable if the values were within requirement of precision (<±15% RSD).


### 2.5.8. Sample Preparation and Test

A plasma sample of 0.2 ml was precisely diluted with methanol to 4 ml, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then, supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength with methanol as a blank control.


### 2.5.9. Pharmacokinetics Study

The values of AUAWC from the blank plasma group and drug groups at different interval time periods were calculated using Origin software. When the mean AUAWC values of drug group were subtracted from that of the blank group, respectively, the increased AUAWC caused by total components was obtained correspondingly and then substituted into the linear equation to get the total components concentration in vivo. The pharmacokinetic models (one- versus two-compartment) were compared according to the AIC rule, with minimum AIC values being regarded as the best representation of the blood concentration-time dynamic data. A compartmental model of total components in rats was proposed by the DAS software. The pharmacokinetic parameters of total components in rats were expressed as mean ± RSD and were compared by the unpaired Student’st-test using the Statistical Package for the Social Science (SPSS, version 18.0). The result was obtained according to the process as showed in Figure 2.Figure 2
The in vivo analysis process of total components by the new method of AUAWC. (1) UV-Vis spectrophotometer for a full spectrum scanning; (2) exported .xl data files and preprocessed; (3) the data preprocessed are then exported into Origin software; (4) the value of AUAWC then were calculated; (5) the concentration acquired by the regression equation and kinetic time were analyzed by DAS 2.0 software; (6) the pharmacokinetic parameters and the concentration-time curves were known.


## 2.5.1. Preparation of Calibration Standards

The reference substance of aconitine was prepared in methanol before use with a total concentration of 213μg/ml. Working solutions were prepared by diluting stock solution with methanol for further concentration series of 42.6, 17.04, 8.52, 4.26, 1.06, and 0.53 μg/ml.


## 2.5.2. Specificity

Specificity of the method was investigated by comparing chromatograms of processed blank plasma samples, the standard of aconitine, the blank plasma spiked with the aconitine, and plasma after oral administration ofAconitum extract. The AUAWC of plasma samples should be larger than that of blank plasma samples, so the interference of blank plasma can be eliminated by the difference value.


## 2.5.3. Linearity

In accordance with the UV-Vis spectrophotometry, methanol was used as the blank control. Each 0.2 ml blank plasma was precisely added above series of standard solutions to 4 ml, respectively, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength. An eight-point calibration curve was constructed by plotting the AUAWC against the concentration. The linearity of the calibration curve was evaluated by linear regression analysis.


## 2.5.4. Recovery

The extraction recovery and relative recovery of aconitine were determined by analyzing six replicates of QC samples at three concentration levels. The extraction recovery was calculated by comparing the AUAWC values (a) of extracted QC samples with those (a) in which the compounds were spiked directly to methanol. The relative recovery was evaluated by comparing the concentration calculated by substituting the AUAWC values (a) into the regression equation with the actual concentration.


## 2.5.5. Precision

The precision of the method was determined by analyzing QC samples at three concentration levels in six replicates. Intraday precision was assessed from replicate analyses (n=6) of QC samples at each concentration level on the same day. The precision was expressed as relative standard deviation (RSD) for each QC concentration. The precisions were required to be within ±15% RSD.


## 2.5.6. Difference

The difference of the blank plasma samples from randomized SD rats in a group was determined. The difference could be ignored if the RSD < ±15%.


## 2.5.7. Stability

The stability of drug plasma samples from rats was determined at different time periods, including their stability after three freeze-thaw cycles with a frozen temperature of −20°C and the stability of processed samples kept at room temperature for 8 h. Samples were considered to be stable if the values were within requirement of precision (<±15% RSD).


## 2.5.8. Sample Preparation and Test

A plasma sample of 0.2 ml was precisely diluted with methanol to 4 ml, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then, supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength with methanol as a blank control.


## 2.5.9. Pharmacokinetics Study

The values of AUAWC from the blank plasma group and drug groups at different interval time periods were calculated using Origin software. When the mean AUAWC values of drug group were subtracted from that of the blank group, respectively, the increased AUAWC caused by total components was obtained correspondingly and then substituted into the linear equation to get the total components concentration in vivo. The pharmacokinetic models (one- versus two-compartment) were compared according to the AIC rule, with minimum AIC values being regarded as the best representation of the blood concentration-time dynamic data. A compartmental model of total components in rats was proposed by the DAS software. The pharmacokinetic parameters of total components in rats were expressed as mean ± RSD and were compared by the unpaired Student’st-test using the Statistical Package for the Social Science (SPSS, version 18.0). The result was obtained according to the process as showed in Figure 2.Figure 2
The in vivo analysis process of total components by the new method of AUAWC. (1) UV-Vis spectrophotometer for a full spectrum scanning; (2) exported .xl data files and preprocessed; (3) the data preprocessed are then exported into Origin software; (4) the value of AUAWC then were calculated; (5) the concentration acquired by the regression equation and kinetic time were analyzed by DAS 2.0 software; (6) the pharmacokinetic parameters and the concentration-time curves were known.


## 3. Results

### 3.1. Validation of the Method

#### 3.1.1. Linearity

From Figure3, there were no interference from endogenous or exogenous materials and linear in the range from 1.02 to 65.00 μg/ml. The typical calibration curve of aconitine in rat plasma was ΔAUAWC = 1.2355C + 3.2935 with a coefficient of correlation r = 0.9993.Figure 3
UV-Vis scan spectrum of total components fromAconitum extract in rats. (1) The blank plasma was illustrated by red line; (2) the drug plasma sample obtained at one hour after a single dose by purple; (3) the drug plasma sample obtained at one hour after a multiple dose by blue; (4) the reference substance aconitine in methanol solution by green; (5) the blank plasma spiked with aconitine by black.


#### 3.1.2. Recovery

Six replicates at low, medium, high QC concentrations for aconitine were prepared for recovery, as shown in Table1. The recoveries of aconitine were satisfactory and reproducible. The mean absolute recovery of aconitine was from 80.45 to 99.52% at three QC levels. The mean relative recovery was from 100.64 to 107.34% for aconitine at three QC levels.Table 1
The recoveries and precision for aconitine in rats plasma (n=6).
Analyte
Spiked concentration (μg/ml)
Extraction recovery
Relative recovery
Precision
Mean (%)
RSD (%)
Mean (%)
RSD (%)
RSD (%)
Aconitine
2.03
99.52
5.44
100.64
7.08
1.30
16.25
81.18
3.01
104.45
3.45
1.05
65.00
80.45
1.26
107.34
1.85
0.75


#### 3.1.3. Precision

The intraprecision values were within ±15% RSD at all QC levels of aconitine in rats plasma as shown in Table1. The data were considered to be acceptable for subsequent analysis of all the samples.


#### 3.1.4. Difference

The UV-Vis scanning spectrum of blank plasma from randomized eight SD rats in single-dose and multidose trials was shown, respectively, in Figures4 and 5. RSD of the AUAWC value was within ±15% as shown in Table 2, which indicated that there is little difference for the determination of the total components in different plasma from different randomized rats.Figure 4
The spectrum of blank plasma from randomized rats in single dose (n=8).Figure 5
The spectrum of blank plasma from randomized rat in multidose (n = 8).Table 2
The AUAWC values of blank plasma from randomized rats (n=8).
Dose
Values of AUAWC
Mean
RSD (%)
Single dose
46.07
45.00
2.00
47.10
43.60
45.03
44.70
44.54
44.34
44.66
Multidose
44.04
44.68
2.20
45.32
44.26
46.84
43.63
46.04
45.19
44.98


#### 3.1.5. Stability

The data in Table3 obtained from determination of stability demonstrated that there was no significant degradation under the conditions tested. The plasma samples were stable at room temperature for 8 h, during three freeze-thaw cycles at −20°C.Table 3
Stability of plasma samples under different storage conditions (n=6).
Storage conditions
Time
AUAWC value
Mean
RSD (%)
At room temperature for 8 h
0
45.145
45.751
2.20
1
44.051
2
45.348
3
46.524
4
46.766
6
45.057
8
47.365
Three freeze-thaw cycles
—
50.136
52.246
2.81
—
54.279
—
52.324


### 3.2. Pharmacokinetics Study

#### 3.2.1. The Concentration-Time Curve

The validated method was applied to the study on pharmacokinetics ofAconitum extract in rats. The full wavelength scan for different plasma samples is illustrated in Figure 3. The mean AUAWC values of blank plasma samples and the AUAWC increased by total components are provided in Table 4. The profile of kinetic curve on concentration versus time in rats after administration is shown in Figures 6 and 7.Table 4
The mean values of AUAWC and concentrations of total components (n=8).
Dose
Time (h)
Mean AUAWC values of plasma
AUAWC values of drug
Concentration (µg/ml)
Single dose
0.00
45.00
0.00
0.00
0.25
45.98
0.98
0.00
0.50
53.71
8.71
4.38
1.00
57.66
12.66
7.58
2.00
58.44
13.44
8.21
4.00
57.71
12.71
7.62
6.00
54.34
9.34
4.89
8.00
52.79
7.79
3.64
12.00
49.13
4.13
0.68
Multiple dose
−48.00
47.18
3.69
0.32
−24.00
48.55
3.84
0.44
0.00
44.68
0.00
0.00
0.25
48.81
4.13
0.68
0.50
52.76
8.08
3.87
1.00
51.81
7.13
3.11
2.00
54.66
9.98
5.41
4.00
52.73
8.05
3.85
6.00
50.14
5.46
1.75
8.00
49.92
5.24
1.58
12.00
47.24
2.56
0.00Figure 6
The profile of concentration-time curve after a single dose (n=8).Figure 7
The profile of concentration-time curve after a multiple dose (n=8).


#### 3.2.2. Pharmacokinetics

The main pharmacokinetic parameters of total components in rats after a single and multiple dose administration ofAconitum extract are shown in Table 5. Comparison of the pharmacokinetic parameters of two groups by the unpaired Student’s t-test revealed significant difference (P<0.05) among the important pharmacokinetic parameters, such as Cmax, AUC0∼48, and half-life (t1/2) in Table 6.Table 5
Pharmacokinetics parameters of total components (mean ± RSD,n=8).
Parameters
Unit
Single dose
Multiple dose
t
1/2
h
4.056 ± 0.026
3.395 ± 0.049
T
max
h
2.000 ± 0.054
2.000 ± 0.175
C
max
µg/ml
8.210 ± 0.386
5.410 ± 0.404
AUC0∼12
µg/ml/h
24.555 ± 0.264
24.901 ± 1.594
AUC0–∞
µg/ml/h
69.731 ± 0.223
32.626 ± 1.601
CL/F
µg/ml/h
0.278 ± 0.092
0.682 ± 0.312
V1/F
mg/µg/ml
1.627 ± 0.123
3.338 ± 0.872
C
av
µg/ml
—
2.075 ± 0.282
AUCss
µg/ml/h
—
24.610 ± 0.422
DF
—
—
2.405 ± 0.175Table 6
Main pharmacokinetic parameters for the statistics and analysis (n=8).
Method
P value
Conclusion
InCmax
Independent samplet-test
0.424
No significance
In AUC0∼12
Independent samplet-test
0.399
No significance
t
1/2
Independent samplet-test
0.300
No significance
T
max
Independent samplet-test
0.106
No significanceFollowing the above figures and tables, the concentration of total components in the fifth and sixth day was lower than the value ofCav, but close to that of 0.25 h after administration in the seventh day during the course of multiple oral dose of Aconitum extract. Meanwhile, the concentration-time curve in rats presented a single-peak phenomenon after a single or multiple oral dose of Aconitum extract. They indicated the concentration of total components decreased quickly after reaching the Cmax. In addition, Tmax of total components stayed the same for 2 h, but t1/2 was 3.395 h after a multiple dose, and there was a trend of decrease compared with single dose; however, no significant difference was seen. The results further demonstrated that the absorption and excretion of total components in rats were rather rapid, which were characterized by the one-compartment model in this study, and they were consistent with the results in the studies [22, 40–42]. From Table 6, there was no significant difference (P>0.05) in those pharmacokinetic parameters between the single-dose group and multiple-dose group. The cumulative ratio of Cmax and AUC0∼t (the value of AUC0∼12 in seventh day divided by that of the first day) were 0.658 and 0.418, and there were no accumulation of total components in rats after continuous administration for 7 d and once a day.


### 3.3. Discussion

From the view of biopharmaceutics, the drug concentration in rat plasma will wave greatly if the rats get a fright with blooding repeatedly, so randomized rats were sampled only one time for a rat and eight rats were divided in a group to improve the accuracy of the data. Moreover, the concentration of total components in the fifth and sixth day was lower than the value ofCav, which demonstrated that the valley concentration of Aconitum extract is a little small, and suggested the dose of sustained-release preparation, which is transformed from Aconitum injection, can be larger than that of injection. UV-Vis scan spectrum can well illustrate absorbance characteristics of total components in TCM, which is better than the method of HPLC in this point.


## 3.1. Validation of the Method

### 3.1.1. Linearity

From Figure3, there were no interference from endogenous or exogenous materials and linear in the range from 1.02 to 65.00 μg/ml. The typical calibration curve of aconitine in rat plasma was ΔAUAWC = 1.2355C + 3.2935 with a coefficient of correlation r = 0.9993.Figure 3
UV-Vis scan spectrum of total components fromAconitum extract in rats. (1) The blank plasma was illustrated by red line; (2) the drug plasma sample obtained at one hour after a single dose by purple; (3) the drug plasma sample obtained at one hour after a multiple dose by blue; (4) the reference substance aconitine in methanol solution by green; (5) the blank plasma spiked with aconitine by black.


### 3.1.2. Recovery

Six replicates at low, medium, high QC concentrations for aconitine were prepared for recovery, as shown in Table1. The recoveries of aconitine were satisfactory and reproducible. The mean absolute recovery of aconitine was from 80.45 to 99.52% at three QC levels. The mean relative recovery was from 100.64 to 107.34% for aconitine at three QC levels.Table 1
The recoveries and precision for aconitine in rats plasma (n=6).
Analyte
Spiked concentration (μg/ml)
Extraction recovery
Relative recovery
Precision
Mean (%)
RSD (%)
Mean (%)
RSD (%)
RSD (%)
Aconitine
2.03
99.52
5.44
100.64
7.08
1.30
16.25
81.18
3.01
104.45
3.45
1.05
65.00
80.45
1.26
107.34
1.85
0.75


### 3.1.3. Precision

The intraprecision values were within ±15% RSD at all QC levels of aconitine in rats plasma as shown in Table1. The data were considered to be acceptable for subsequent analysis of all the samples.


### 3.1.4. Difference

The UV-Vis scanning spectrum of blank plasma from randomized eight SD rats in single-dose and multidose trials was shown, respectively, in Figures4 and 5. RSD of the AUAWC value was within ±15% as shown in Table 2, which indicated that there is little difference for the determination of the total components in different plasma from different randomized rats.Figure 4
The spectrum of blank plasma from randomized rats in single dose (n=8).Figure 5
The spectrum of blank plasma from randomized rat in multidose (n = 8).Table 2
The AUAWC values of blank plasma from randomized rats (n=8).
Dose
Values of AUAWC
Mean
RSD (%)
Single dose
46.07
45.00
2.00
47.10
43.60
45.03
44.70
44.54
44.34
44.66
Multidose
44.04
44.68
2.20
45.32
44.26
46.84
43.63
46.04
45.19
44.98


### 3.1.5. Stability

The data in Table3 obtained from determination of stability demonstrated that there was no significant degradation under the conditions tested. The plasma samples were stable at room temperature for 8 h, during three freeze-thaw cycles at −20°C.Table 3
Stability of plasma samples under different storage conditions (n=6).
Storage conditions
Time
AUAWC value
Mean
RSD (%)
At room temperature for 8 h
0
45.145
45.751
2.20
1
44.051
2
45.348
3
46.524
4
46.766
6
45.057
8
47.365
Three freeze-thaw cycles
—
50.136
52.246
2.81
—
54.279
—
52.324


## 3.1.1. Linearity

From Figure3, there were no interference from endogenous or exogenous materials and linear in the range from 1.02 to 65.00 μg/ml. The typical calibration curve of aconitine in rat plasma was ΔAUAWC = 1.2355C + 3.2935 with a coefficient of correlation r = 0.9993.Figure 3
UV-Vis scan spectrum of total components fromAconitum extract in rats. (1) The blank plasma was illustrated by red line; (2) the drug plasma sample obtained at one hour after a single dose by purple; (3) the drug plasma sample obtained at one hour after a multiple dose by blue; (4) the reference substance aconitine in methanol solution by green; (5) the blank plasma spiked with aconitine by black.


## 3.1.2. Recovery

Six replicates at low, medium, high QC concentrations for aconitine were prepared for recovery, as shown in Table1. The recoveries of aconitine were satisfactory and reproducible. The mean absolute recovery of aconitine was from 80.45 to 99.52% at three QC levels. The mean relative recovery was from 100.64 to 107.34% for aconitine at three QC levels.Table 1
The recoveries and precision for aconitine in rats plasma (n=6).
Analyte
Spiked concentration (μg/ml)
Extraction recovery
Relative recovery
Precision
Mean (%)
RSD (%)
Mean (%)
RSD (%)
RSD (%)
Aconitine
2.03
99.52
5.44
100.64
7.08
1.30
16.25
81.18
3.01
104.45
3.45
1.05
65.00
80.45
1.26
107.34
1.85
0.75


## 3.1.3. Precision

The intraprecision values were within ±15% RSD at all QC levels of aconitine in rats plasma as shown in Table1. The data were considered to be acceptable for subsequent analysis of all the samples.


## 3.1.4. Difference

The UV-Vis scanning spectrum of blank plasma from randomized eight SD rats in single-dose and multidose trials was shown, respectively, in Figures4 and 5. RSD of the AUAWC value was within ±15% as shown in Table 2, which indicated that there is little difference for the determination of the total components in different plasma from different randomized rats.Figure 4
The spectrum of blank plasma from randomized rats in single dose (n=8).Figure 5
The spectrum of blank plasma from randomized rat in multidose (n = 8).Table 2
The AUAWC values of blank plasma from randomized rats (n=8).
Dose
Values of AUAWC
Mean
RSD (%)
Single dose
46.07
45.00
2.00
47.10
43.60
45.03
44.70
44.54
44.34
44.66
Multidose
44.04
44.68
2.20
45.32
44.26
46.84
43.63
46.04
45.19
44.98


## 3.1.5. Stability

The data in Table3 obtained from determination of stability demonstrated that there was no significant degradation under the conditions tested. The plasma samples were stable at room temperature for 8 h, during three freeze-thaw cycles at −20°C.Table 3
Stability of plasma samples under different storage conditions (n=6).
Storage conditions
Time
AUAWC value
Mean
RSD (%)
At room temperature for 8 h
0
45.145
45.751
2.20
1
44.051
2
45.348
3
46.524
4
46.766
6
45.057
8
47.365
Three freeze-thaw cycles
—
50.136
52.246
2.81
—
54.279
—
52.324


## 3.2. Pharmacokinetics Study

### 3.2.1. The Concentration-Time Curve

The validated method was applied to the study on pharmacokinetics ofAconitum extract in rats. The full wavelength scan for different plasma samples is illustrated in Figure 3. The mean AUAWC values of blank plasma samples and the AUAWC increased by total components are provided in Table 4. The profile of kinetic curve on concentration versus time in rats after administration is shown in Figures 6 and 7.Table 4
The mean values of AUAWC and concentrations of total components (n=8).
Dose
Time (h)
Mean AUAWC values of plasma
AUAWC values of drug
Concentration (µg/ml)
Single dose
0.00
45.00
0.00
0.00
0.25
45.98
0.98
0.00
0.50
53.71
8.71
4.38
1.00
57.66
12.66
7.58
2.00
58.44
13.44
8.21
4.00
57.71
12.71
7.62
6.00
54.34
9.34
4.89
8.00
52.79
7.79
3.64
12.00
49.13
4.13
0.68
Multiple dose
−48.00
47.18
3.69
0.32
−24.00
48.55
3.84
0.44
0.00
44.68
0.00
0.00
0.25
48.81
4.13
0.68
0.50
52.76
8.08
3.87
1.00
51.81
7.13
3.11
2.00
54.66
9.98
5.41
4.00
52.73
8.05
3.85
6.00
50.14
5.46
1.75
8.00
49.92
5.24
1.58
12.00
47.24
2.56
0.00Figure 6
The profile of concentration-time curve after a single dose (n=8).Figure 7
The profile of concentration-time curve after a multiple dose (n=8).


### 3.2.2. Pharmacokinetics

The main pharmacokinetic parameters of total components in rats after a single and multiple dose administration ofAconitum extract are shown in Table 5. Comparison of the pharmacokinetic parameters of two groups by the unpaired Student’s t-test revealed significant difference (P<0.05) among the important pharmacokinetic parameters, such as Cmax, AUC0∼48, and half-life (t1/2) in Table 6.Table 5
Pharmacokinetics parameters of total components (mean ± RSD,n=8).
Parameters
Unit
Single dose
Multiple dose
t
1/2
h
4.056 ± 0.026
3.395 ± 0.049
T
max
h
2.000 ± 0.054
2.000 ± 0.175
C
max
µg/ml
8.210 ± 0.386
5.410 ± 0.404
AUC0∼12
µg/ml/h
24.555 ± 0.264
24.901 ± 1.594
AUC0–∞
µg/ml/h
69.731 ± 0.223
32.626 ± 1.601
CL/F
µg/ml/h
0.278 ± 0.092
0.682 ± 0.312
V1/F
mg/µg/ml
1.627 ± 0.123
3.338 ± 0.872
C
av
µg/ml
—
2.075 ± 0.282
AUCss
µg/ml/h
—
24.610 ± 0.422
DF
—
—
2.405 ± 0.175Table 6
Main pharmacokinetic parameters for the statistics and analysis (n=8).
Method
P value
Conclusion
InCmax
Independent samplet-test
0.424
No significance
In AUC0∼12
Independent samplet-test
0.399
No significance
t
1/2
Independent samplet-test
0.300
No significance
T
max
Independent samplet-test
0.106
No significanceFollowing the above figures and tables, the concentration of total components in the fifth and sixth day was lower than the value ofCav, but close to that of 0.25 h after administration in the seventh day during the course of multiple oral dose of Aconitum extract. Meanwhile, the concentration-time curve in rats presented a single-peak phenomenon after a single or multiple oral dose of Aconitum extract. They indicated the concentration of total components decreased quickly after reaching the Cmax. In addition, Tmax of total components stayed the same for 2 h, but t1/2 was 3.395 h after a multiple dose, and there was a trend of decrease compared with single dose; however, no significant difference was seen. The results further demonstrated that the absorption and excretion of total components in rats were rather rapid, which were characterized by the one-compartment model in this study, and they were consistent with the results in the studies [22, 40–42]. From Table 6, there was no significant difference (P>0.05) in those pharmacokinetic parameters between the single-dose group and multiple-dose group. The cumulative ratio of Cmax and AUC0∼t (the value of AUC0∼12 in seventh day divided by that of the first day) were 0.658 and 0.418, and there were no accumulation of total components in rats after continuous administration for 7 d and once a day.


## 3.2.1. The Concentration-Time Curve

The validated method was applied to the study on pharmacokinetics ofAconitum extract in rats. The full wavelength scan for different plasma samples is illustrated in Figure 3. The mean AUAWC values of blank plasma samples and the AUAWC increased by total components are provided in Table 4. The profile of kinetic curve on concentration versus time in rats after administration is shown in Figures 6 and 7.Table 4
The mean values of AUAWC and concentrations of total components (n=8).
Dose
Time (h)
Mean AUAWC values of plasma
AUAWC values of drug
Concentration (µg/ml)
Single dose
0.00
45.00
0.00
0.00
0.25
45.98
0.98
0.00
0.50
53.71
8.71
4.38
1.00
57.66
12.66
7.58
2.00
58.44
13.44
8.21
4.00
57.71
12.71
7.62
6.00
54.34
9.34
4.89
8.00
52.79
7.79
3.64
12.00
49.13
4.13
0.68
Multiple dose
−48.00
47.18
3.69
0.32
−24.00
48.55
3.84
0.44
0.00
44.68
0.00
0.00
0.25
48.81
4.13
0.68
0.50
52.76
8.08
3.87
1.00
51.81
7.13
3.11
2.00
54.66
9.98
5.41
4.00
52.73
8.05
3.85
6.00
50.14
5.46
1.75
8.00
49.92
5.24
1.58
12.00
47.24
2.56
0.00Figure 6
The profile of concentration-time curve after a single dose (n=8).Figure 7
The profile of concentration-time curve after a multiple dose (n=8).


## 3.2.2. Pharmacokinetics

The main pharmacokinetic parameters of total components in rats after a single and multiple dose administration ofAconitum extract are shown in Table 5. Comparison of the pharmacokinetic parameters of two groups by the unpaired Student’s t-test revealed significant difference (P<0.05) among the important pharmacokinetic parameters, such as Cmax, AUC0∼48, and half-life (t1/2) in Table 6.Table 5
Pharmacokinetics parameters of total components (mean ± RSD,n=8).
Parameters
Unit
Single dose
Multiple dose
t
1/2
h
4.056 ± 0.026
3.395 ± 0.049
T
max
h
2.000 ± 0.054
2.000 ± 0.175
C
max
µg/ml
8.210 ± 0.386
5.410 ± 0.404
AUC0∼12
µg/ml/h
24.555 ± 0.264
24.901 ± 1.594
AUC0–∞
µg/ml/h
69.731 ± 0.223
32.626 ± 1.601
CL/F
µg/ml/h
0.278 ± 0.092
0.682 ± 0.312
V1/F
mg/µg/ml
1.627 ± 0.123
3.338 ± 0.872
C
av
µg/ml
—
2.075 ± 0.282
AUCss
µg/ml/h
—
24.610 ± 0.422
DF
—
—
2.405 ± 0.175Table 6
Main pharmacokinetic parameters for the statistics and analysis (n=8).
Method
P value
Conclusion
InCmax
Independent samplet-test
0.424
No significance
In AUC0∼12
Independent samplet-test
0.399
No significance
t
1/2
Independent samplet-test
0.300
No significance
T
max
Independent samplet-test
0.106
No significanceFollowing the above figures and tables, the concentration of total components in the fifth and sixth day was lower than the value ofCav, but close to that of 0.25 h after administration in the seventh day during the course of multiple oral dose of Aconitum extract. Meanwhile, the concentration-time curve in rats presented a single-peak phenomenon after a single or multiple oral dose of Aconitum extract. They indicated the concentration of total components decreased quickly after reaching the Cmax. In addition, Tmax of total components stayed the same for 2 h, but t1/2 was 3.395 h after a multiple dose, and there was a trend of decrease compared with single dose; however, no significant difference was seen. The results further demonstrated that the absorption and excretion of total components in rats were rather rapid, which were characterized by the one-compartment model in this study, and they were consistent with the results in the studies [22, 40–42]. From Table 6, there was no significant difference (P>0.05) in those pharmacokinetic parameters between the single-dose group and multiple-dose group. The cumulative ratio of Cmax and AUC0∼t (the value of AUC0∼12 in seventh day divided by that of the first day) were 0.658 and 0.418, and there were no accumulation of total components in rats after continuous administration for 7 d and once a day.


## 3.3. Discussion

From the view of biopharmaceutics, the drug concentration in rat plasma will wave greatly if the rats get a fright with blooding repeatedly, so randomized rats were sampled only one time for a rat and eight rats were divided in a group to improve the accuracy of the data. Moreover, the concentration of total components in the fifth and sixth day was lower than the value ofCav, which demonstrated that the valley concentration of Aconitum extract is a little small, and suggested the dose of sustained-release preparation, which is transformed from Aconitum injection, can be larger than that of injection. UV-Vis scan spectrum can well illustrate absorbance characteristics of total components in TCM, which is better than the method of HPLC in this point.


## 4. Conclusion

The method of AUAWC used is feasible for the in vivo evaluation study on total components ofAconitum with a convenience, quickness, and specificity response. In this study, compared with single dose, there were no significant change of the pharmacokinetic behavior and no risk of drug accumulation after continuous administration of Aconitum extract, which is beneficial to the research on sustained-release preparation of Aconitum and other TCMs.



---

*Source: 6385165-2019-02-03.xml*